Purification of active human plasminogen activator inhibitor 1 from Escherichia coli
- 1 December 1989
- journal article
- research article
- Published by Wiley in European Journal of Biochemistry
- Vol. 186 (3) , 523-533
- https://doi.org/10.1111/j.1432-1033.1989.tb15238.x
Abstract
Plasminogen activator inhibitor 1 (PAI-1) inhibits both tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) and, therefore, is an important regulator of plasminogen activation. We have developed eucaryotic and procaryotic expression systems for PAI-1 and characterized the recombinant glycosylated and non-glycosylated products, together with a non-recombinant natural control, produced in the histosarcoma cell line HT 1080. For eucaryotic expression, the PAI-1 cDNA was stably transfected into chinese hamster ovary cells (CHO cells), while procaryotic expression in Escherichia coli was examined after inserting the DNA sequence encoding the mature PAI-1 protein into an indubile expression vector. Recombinant PAI-1 from CHO cells was purified approximately 50-fold in two steps and was indistinguishable from natural PAI-1. Between 3% and 4% of total cellular protein in the procaryotic expression system consisted of PAI-1, from which it was purified approximately 30-fold, with yields of between 15% and 20%. This PAI-1 formed 1:1 complexes with uPA and also with the single- and two-chain forms of tPA. Kinetic analysis demonstrated that the procaryote-produced PAI-I had an inhibitory activity towards all three forms of PA that resembled that of natural PAI-1 with association rate constants of approximately 107 M-1 s-1. In contrast to PAI-1 from eucaryotic cells, the PAI-1 from E. coli had had an inherent activity equal to that of guanidine/HCl-activated natural PAI-1. The activity could not be increased by tratment with denaturants suggesting that the latent form of PAI-1 was absent. However, at 37.degree.C the procaryote-produced PAI-1 lost activity at the same rate as natural PAI-1, with approximately 50% of the activity remaining after 3 h. This activity could be partially restored by treatment with 4 M guanidine/HCl. E. coli-derived PAI-1, added to human plasma and fractionated by Sephacryl S-200 chromatography, eluted in two peaks that were similar to those obtained with guanidine-activated PAI-1 from eucaryotic cells, suggesting that it bound to the PAI-1-binding protein (vitronectin).This publication has 68 references indexed in Scilit:
- Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasmaFEBS Letters, 1988
- Hormone binding globulins undergo serpin conformational change in inflammationNature, 1988
- Purification and characterization of natural and recombinant human plasminogen activator inhibitor‐1 (PAI‐1)European Journal of Biochemistry, 1988
- Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencingFEBS Letters, 1986
- Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucoseCell, 1986
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Patterns of Amino Acids near Signal‐Sequence Cleavage SitesEuropean Journal of Biochemistry, 1983
- A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha1-proteinase inhibitorBiochemical and Biophysical Research Communications, 1980
- Analysis of gene control signals by DNA fusion and cloning in Escherichia coliJournal of Molecular Biology, 1980
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970